Survival Motor Neuron-2-directed RNA Interaction Drug Class List

Drugs in Drug Class: Survival Motor Neuron-2-directed RNA Interaction

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-001	Dec 23, 2016		RX	Yes	Yes	9,717,750
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-003	Mar 27, 2026		RX	Yes	Yes
Biogen	SPINRAZA	nusinersen sodium	SOLUTION;INTRATHECAL	209531-002	Mar 27, 2026		RX	Yes	Yes	8,980,853

Last updated: June 27, 2026

Executive summary

Survival Motor Neuron-2 (SMN2)–directed RNA interaction drugs are led by nusinersen (Spinraza) and risdiplam (Evrysdi). The core patent estate is anchored by (1) antisense oligonucleotide (ASO) chemistry and SMN2 pre-mRNA–splicing modulation for nusinersen and (2) small-molecule SMN2 splicing corrector IP for risdiplam. Commercially, both products remain exposed to competitive pressure from (a) follow-on ASOs and splicing-corrector analogs, (b) next-generation delivery platforms for ASO, and (c) potential late-therapy entrants targeting the same SMN2 splicing event. In market-structure terms, the near-term “dynamic” risk is less about immediate biosimilar substitution and more about incremental splicing-correction IP and regulatory competition via FDA approvals that can erode pricing power before full exclusivity expiry.

---

What patents protect SMN2-directed RNA interaction drugs like nusinersen and risdiplam?

The SMN2 RNA interaction class covers two dominant mechanisms: ASO-mediated SMN2 exon 7 splicing and small-molecule modulation of SMN2 pre-mRNA splicing. Patent coverage generally clusters into: (i) target sequence and splicing modulation logic, (ii) chemical modifications and ASO structure, (iii) formulation and delivery, (iv) manufacturing and purification, and (v) use or dosing regimens.

What patents protect nusinersen (Spinraza)

Key IP themes for nusinersen include:

• ASO sequence and SMN2 exon 7 targeting for increased inclusion of exon 7 in SMN2 transcripts
• Oligonucleotide chemistry (stabilizing backbone and sugar modifications)
• Methods of modulating SMN2 splicing using the ASO
• Formulation and administration approaches (intrathecal delivery and relevant pharmaceutical compositions)

Commercial relevance: nusinersen’s patent estate has historically been the primary barrier against immediate “generic ASO” substitutes, because entry requires both a valid process/chemistry landscape and product-specific claims that are often sequence- and modification-dependent.

What patents protect risdiplam (Evrysdi)

Key IP themes for risdiplam include:

• Small-molecule binding and splicing correction of SMN2
• Compound claims and chemical series around the active moiety
• Compositions containing the small molecule
• Methods of treating SMA using the compound, typically linked to clinical effect endpoints

Commercial relevance: small molecules can be harder to “design around” if the patent claims include structural and functional language tied to SMN2 splicing modulation. However, they create competitive openings for alternative chemotypes that reach the same biological endpoint via different binding modes.

---

How many patents cover SMN2 splicing correctors and what is the typical claim coverage?

Across the SMN2-directed RNA interaction space, estates tend to be layered, with multiple active patent families controlling different aspects of the product. Coverage often spans:

• Core composition (ASO sequence and/or small-molecule structure)
• Chemical modifications (backbone, sugar, linkages, terminal modifications)
• Therapeutic method-of-use claims (treating SMA, improving motor function, treating presymptomatic or infant-onset disease)
• Formulation and administration (where applicable, especially for ASO intrathecal delivery)
• Manufacturing (process steps, purification, and specifications)

Actionable dynamic: for investment and licensing decisions, the practical blocking point is rarely “one patent.” It is the intersection of (1) sequence/structure claim space, (2) formulation and dosing claims, and (3) method-of-use claims that can support injunctions or regulatory leverage.

---

When does SMN2 RNA interaction exclusivity end for nusinersen and risdiplam?

Featured-snippet style answer: exclusivity timelines are driven by regulatory exclusivity (e.g., new chemical entity or biologic exclusivity where applicable) plus patent term and any pediatric extensions.

Timeline mechanics that matter for market dynamics

1. Regulatory exclusivity can limit FDA generic/sponsor pathways even if some patents expire.
2. Patent expiry determines whether a competitor can launch a product that stays outside claim scope.
3. Pediatric exclusivity and PTA can extend effective launch windows.
4. Patent litigation timelines can accelerate or delay market entry via settlement or injunction risk.

Practical take: Even after core composition patents expire, follow-on claims around specific modifications, formulations, or dosing can preserve monetization and extend effective exclusivity.

---

What generic entry risks exist for SMN2-directed RNA interaction drugs?

Can biosimilars substitute nusinersen or risdiplam?

• Biosimilar pathway risk: generally low because neither product is a biologic in the biosimilar sense (nusinersen is an ASO; risdiplam is a small molecule).
• Generic/SNDAs: for risdiplam, normal small-molecule generic logic applies. For nusinersen, “generic ASO” risk is constrained by sequence-specific and chemistry-specific claims, plus complex formulation and administration needs.

Entry risks that do matter

• “Design-around” ASOs that target the same SMN2 splicing event through different sequences or modifications may still infringe if claims are broad or cover functional splicing outcomes.
• Section viii carve-outs: competitors may try to avoid method-of-use claims by focusing on different dosing regimens or patient populations, but method claims can still be infringed if labels overlap or clinical use mirrors the claimed method.
• ANDA-type challenges: for small molecules like risdiplam, generic entry risk is primarily a function of patent challenges and whether patents are still enforceable at launch.

---

What is the Orange Book status of nusinersen and risdiplam?

What Orange Book listings typically show for this class

• For risdiplam, Orange Book listings generally include patents tied to the approved drug product and/or methods. This drives Paragraph IV strategy and FDA launch timing.
• For nusinersen, the listing may be handled through the NDA route and the patent listing regime; the operative factor is still which patents are listed and whether they cover product composition, method of use, or both.

Market dynamic: Orange Book listings directly affect how quickly generics can initiate challenges and how settlement leverage is structured.

---

What patent litigation affects SMN2 RNA interaction drugs and how does it shape settlements?

SMN2 RNA interaction litigation has historically centered on core composition and splicing-modulation claims, plus downstream formulation and method-of-use coverage. Litigation influences market dynamics through:

• Injunction leverage that can delay launch even after some patent expiries
• Settlement triggers that specify “carve-out dates” and authorized launch windows
• Scope limits in licensing deals that restrict design-around space

Deal dynamic: for a competitor, winning early can unlock commercial entry; losing can be used as a pricing support mechanism by the reference product owner while follow-on R&D continues.

---

Which companies are challenging or preparing competing SMN2 splicing correctors?

The competitive set typically includes:

• ASO developers pursuing exon 7 splicing correction with alternate chemistries or sequences
• small-molecule splicing corrector developers targeting SMN2 through distinct binding and splicing modulation approaches
• delivery-platform innovators seeking improved CNS exposure, dosing frequency, or formulation stability

Business relevance: competitor readiness is shaped by the patent “gates” covering chemistry and function. Even if clinical differentiation exists, IP can control timeline and market access.

---

How do SMN2 RNA interaction drugs compare on IP barrier height and regulatory speed?

Nusinersen (ASO)

• IP barrier height: high due to sequence and chemistry-specific claims plus manufacturing complexity.
• Regulatory speed: established and commercially scaled; incremental entrants face both approval and IP risks.
• Competitive implication: follow-on ASOs need meaningful differentiation that avoids infringement while proving safety and efficacy.

Risdiplam (small molecule)

• IP barrier height: medium-to-high depending on claim scope; small-molecule claims can still be strong but can be contestable via design-around or patent challenge.
• Regulatory speed: easier to make generic-type variants in principle, but patent listings and method claims can delay entry.
• Competitive implication: the key watch item is the patent landscape around risdiplam’s core small-molecule structure, compositions, and methods.

---

What formulations are protected by patents for SMN2-directed RNA interaction drugs?

Patent estates commonly cover:

• For ASOs: intrathecal delivery-compatible compositions, buffers, and stability-related formulation components, plus quality specs and manufacturing steps.
• For small molecules: oral dosage form compositions, excipients, and potentially particle form or polymorph-adjacent claims where relevant.

Market dynamic: formulation patents can preserve exclusivity even when active-ingredient patents narrow, because competitors must still launch a product within the permitted composition space.

---

How strong is the patent estate for SMN2-directed RNA interaction products?

Strength drivers

• Multiplicity of families: multiple overlapping patent families across chemistry, method, and formulation increases the “stack height.”
• Breadth of functional claims: claims framed around SMN2 splicing outcomes can be harder to design around.
• Regulatory attachment: patents listed to the approved product can create strong FDA-linked leverage.

Weakness drivers

• Narrow claim coverage: if claims are highly sequence-specific (for ASOs) or structurally narrow (for small molecules), competitors can design around if they avoid literal infringement and withstand doctrine-of-equivalents theories.
• Settlement normalization: if patent owners repeatedly settle, the market can shift from litigation to scheduled launch planning.

---

What manufacturing/IP barriers can block SMN2 competitors even if patents expire?

Even when certain patents expire, practical barriers can delay entry:

• Reproducibility of ASO quality and specifications
• Control of impurities and batch consistency
• Validation of CNS exposure and dose-response in humans
• Process patents that survive beyond composition expiration in some estates

Competitive implication: for investors and licensors, the barrier is often not just patent expiry but whether competitors can execute compliant, patent-safe manufacturing.

---

Key takeaways

• The SMN2-directed RNA interaction market is primarily a two-product system: nusinersen (ASO) and risdiplam (small molecule), with IP estates structured around splicing modulation mechanism plus composition and formulation.
• Market dynamics are governed by effective exclusivity that blends regulatory protections with a stacked patent portfolio, not a single “expiration date.”
• The most realistic competitive threat comes from follow-on ASOs/small-molecule splicing correctors that can navigate both composition and method-of-use claims.
• Litigation history and Orange Book-style patent listings shape the practical entry window via Paragraph IV strategy, injunction risk, and settlement “launch date” terms.

---

FAQs

1) Are there biosimilar pathways for nusinersen or risdiplam?

No. Neither product is a standard biologic reference for biosimilar development; substitution risk is driven by generic or copycat product approaches and patent challenges.

2) What patent types most often block “generic-like” entry for SMN2 ASOs?

Sequence/chemistry claims, plus method-of-use and formulation-specific claims tied to clinical administration and splicing modulation outcomes.

3) What’s the most important Orange Book signal for risdiplam entry timing?

The specific patents listed against the approved product that cover active ingredient, formulation, and methods of use, which govern challenge and settlement leverage.

4) Can competitors avoid method-of-use infringement by changing the patient population?

Method claims often tie to the act of treating SMA broadly, so label overlap and real-world use patterns can still create infringement exposure.

5) What drives valuation of a new SMN2 splicing corrector beyond clinical data?

The patent landscape on the splicing target mechanism, composition scope, and formulation or process IP that can constrain launch timing even after clinical proof.

---

References (APA)

No sources were provided in the prompt, and no external documents can be cited reliably without specific patent numbers, FDA labels, Orange Book entries, or litigation dockets.